LACTERA Therapeutics, Inc. is a U.S. biotechnology company advancing science-driven, cell-free bioactive solutions for wound healing, tissue repair, and regenerative healthcare. Built upon proprietary fermentation technology, peer-reviewed clinical trials, and real-world validation, LACTERA bridges scientific innovation with clinical practice to improve outcomes for patients with acute and chronic wounds.
To establish a globally recognized biotechnology platform delivering innovative, evidence-based wound care and regenerative solutions that improve patient recovery worldwide.
Across the globe, millions of patients suffering from diabetic foot ulcers, chronic non-healing wounds, post-surgical defects, and complex burns face prolonged recovery cycles, antimicrobial resistance, and limited access to cold-chain-dependent biologics.
LACTERA Therapeutics, Inc. was founded to address critical unmet clinical needs in complex wound care—where conventional passive dressings fail to resolve stalled healing, and antimicrobial agents risk cytotoxicity or resistance.
By integrating microecological modulation with plant-derived extracellular matrix (ECM) simulation, our platform supports natural tissue repair without live bacteria, antibiotics, heavy-metal ions, or cold-chain infrastructure.
Organized as a U.S. Delaware C-Corporation, LACTERA serves as the central platform for global intellectual property stewardship, international clinical research collaboration, and strategic commercialization.
Developed through multi-strain anaerobic co-culture fermentation (Bifidobacterium and Lactobacillus species with plant-based soybean substrate), LACTERA’s cell-free filtrate functions via dual physical and microenvironmental mechanisms.
Enriched with natural organic acids (pH 3.3–3.6), the fluidic barrier maintains a physiological mildly acidic wound microenvironment and creates a physical impediment to bacterial quorum-sensing and biofilm colonization without heavy-metal cytotoxicity.
100% plant-derived soybean matrix eliminates zoonotic cross-infection risks. Low-molecular-weight bioactive peptides (<1 kDa) and plant-derived extracellular vesicles structurally mimic human ECM to support fibroblast migration and orderly re-epithelialization.
Calibrated 360° mist delivery (0.14 mL/spray) conforms uniformly to deep, irregular wound beds. Ambient stability across 2°C–40°C for 36 months eliminates cold-chain requirements and integrates into standard care protocols in 60 seconds.
Our scientific framework is anchored in quantitative analytical sequencing (LC-MS, LC-UV, NanoFCM), standardized international nomenclature, and peer-reviewed clinical investigation presented at leading global wound healing forums, including the World Union of Wound Healing Societies (WUWHS 2026 Congress).
The safety and clinical performance of the LACTERA® bioactive dressing system have been evaluated across prospective randomized controlled trials, multi-center cohort studies, and longitudinal safety assessments.
British Journal of Dermatology (2026)
ClinicalTrials.gov: NCT07008573
Achieved 94% complete wound healing at 24 weeks vs. 64% in control (P = 0.003), reducing mean time to full closure from 165.9 days to 89.6 days (P = 0.012).
Journal of Wound Care (2026) & WUWHS 2026
Significantly reduced mean donor site healing time from 17 days down to 11 days (~35% reduction), lowering dressing change frequency and patient discomfort.
JWC (2023) & SCMJ (2025)
Achieved 83% complete healing within 16 weeks in DFU cohorts with PAOD/ESRD (mean 51 days), with 0% clinical adverse events across longitudinal safety tracking.
| Outcome | Bottle A (n = 36) |
Bottle B (n = 22) |
P-value |
|---|---|---|---|
| Complete healing by 24 weeks, n (%) | 34 (94) | 14 (64) | 0.003 |
| Mean days to full healing, mean (SD) | 89.6 (17.6) | 165.9 (68.3) | 0.012 |
| Wound area reduction, mean (SD), days | |||
| 25% reduction | 22.4 (5.46) | 30.8 (14.00) | 0.032 |
| 50% reduction | 29.4 (7.35) | 49.7 (23.17) | 0.028 |
| 75% reduction | 49.0 (12.25) | 84.0 (31.14) | 0.021 |
| 100% reduction | 89.6 (17.64) | 165.9 (68.25) | 0.012 |
| Healing at specific timepoints, n (%) | |||
| 4 weeks | 6 (17) | 3 (14) | 0.757 |
| 8 weeks | 15 (42) | 7 (32) | 0.453 |
| 12 weeks | 21 (58) | 8 (36) | 0.104 |
| 16 weeks | 25 (69) | 9 (41) | 0.032 |
| 20 weeks | 33 (92) | 10 (45) | < 0.001 |
| 24 weeks | 34 (94) | 14 (64) | 0.003 |
LACTERA Therapeutics maintains a disciplined intellectual property architecture designed to safeguard core biological manufacturing processes against reverse engineering while establishing durable commercial barriers.
To protect proprietary process advantages, our multi-strain anaerobic co-culture parameters, microbial acclimation protocols, exact compositional ratios, and cell-free extraction methods are strictly maintained as confidential trade secrets and undisclosed proprietary know-how.
LACTERA combines established real-world healthcare utilization with an asset-light international expansion model built around clinical partnerships, local sterile filling collaborations, and technology licensing.
Corporate headquarters (Delaware C-Corporation), global IP governance, scientific affairs coordination, and institutional investor relations.
Ongoing complex wound care clinical collaboration and asset-light local sterile filling & regulatory partnerships (ISO 13485 partner model).
Established commercial utilization and real-world clinical experience supporting ongoing product validation and international expansion.
LACTERA Therapeutics is guided by an international team integrating corporate strategy, peer-reviewed clinical research, and cross-border healthcare operations.
Leads corporate governance, global intellectual property strategy, institutional partnerships, and capital allocation under a U.S. Delaware C-Corporation structure, focusing on scalable international commercialization pathways.
Comprises principal investigators and clinical specialists in dermatology, reconstructive surgery, and complex wound care who have authored peer-reviewed studies in BJD and JWC and presented at the WUWHS Congress.
Oversees formulation standardization, ambient stability validation (2°C–40°C), quality compliance, and clinical deployment across healthcare centers and international medical networks.
* Detailed executive biographies, curriculum vitae, and principal investigator credentials are available to qualified institutional investors and clinical partners upon request under a Mutual NDA.
LACTERA welcomes dialogue with institutional healthcare investors, biotechnology venture funds, family offices, corporate venture groups, and international clinical or licensing partners.
For investor materials, research collaboration proposals, or licensing inquiries under Mutual NDA, please contact our executive office directly.